

Kansas City University IBC

MEETING MINUTES

June 25, 2026

SEP 413-A

The meeting was called to order on June 25, 2026 at 12:40 PM and a quorum was present.

ATTENDANCE

Voting Members Present:

Abdulkaki Agbas	Chair, Scientific
Douglas Bittel	Scientific
Melissa Cobb	Alternate Member, rDNA Animal Containment Expert
Terry Jensen	Biological Safety Officer
George Kolo	Scientific
Farida Mehrhoff	Alternate Member, Scientific
Karen Wiederaenders	Community Member, Non-Affiliated, Non-Scientific

Non-Voting Attendees, Staff and Guests Present:

Dalal Canyon	Research Compliance
--------------	---------------------

Recording:

Lois Benge-Fortin	Staff
-------------------	-------

ITEMS

1 Call to Order

██████████ called the meeting to order at 12:40 p.m. and quorum was present. Few of the committee members attended via zoom

2 Conflicts of Interest Disclosure

██████████ both disclosed conflicts of interest and agreed to recuse themselves when the their protocols were brought forward for discussion.

3 Next Meeting Date and General Announcements

3.1 Next IBC meeting is scheduled on July 23 , 2026 at 12:30 p.m. in SEP 413-A

4 Minutes Review

4.1 Review of May 21, 2026 IBC Meeting Minutes

Review Type: Full Committee Review
Action: Approved
Effective Date: June 25, 2026
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;

Discussion and Remarks:

██████████ made a motion to approve May 21, 2026 IBC meeting minutes and ██████████ seconded. The minutes were approved unanimously.

5 IBC Action Since Last Meeting

5.1 [2359680-3] Cadaveric Anatomical Research Framework ██████████

PI: Sara Sloan, DC
Submission Type: Other

Review Type: Administrative Review
Action: Approved
Effective Date: May 15, 2026
Project Status: Active
Project Expiration: September 24, 2026

██████████ ██████████
██████████ ██████████

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved ██████████

██████████
I ██████████
I ██████████

5.2 [2185780-21] Cadaveric Anatomical Research Framework

PI: Robert Hillard, MD
Submission Type: Other

Review Type: Administrative Review
Action: Withdrawn
Effective Date: May 20, 2026
Project Status: Active
Project Expiration: May 21, 2026

Discussion and Remarks:

The PI requested to withdraw the package and the IBC Office administratively withdrew it on 05/20/2026.

5.3 [1460774-39] Lipolysis regulates metabolic plasticity and stress response of aging human fibroblasts

PI: Ehab Sarsour, MSc, PhD

[REDACTED]

[REDACTED]

Submission Type: Other

Review Type: Administrative Review

Action: Approved

Effective Date: May 15, 2026

Project Status: Active

Project Expiration: July 23, 2026

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]

[REDACTED]

I [REDACTED]

I [REDACTED]

5.4 [1194016-53] scaRNAs regulate spliceosome fidelity, alternative splicing of mRNA and embryological development.

PI: Douglas Bittel, Ph.D.

[REDACTED]

[REDACTED]

Submission Type: Other

Review Type: Administrative Review

Action: Approved

Effective Date: June 9, 2026

Project Status: Active

Project Expiration: February 18, 2027

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]

[REDACTED]

I [REDACTED]

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

5.5 [506158-55] Gene therapy of Severe Muscular dystrophy (DMD) Mouse Model

PI: Robert White, PhD
Submission Type: Other

Review Type: Administrative Review
Action: Approved
Effective Date: May 15, 2026
Project Status: Active
Project Expiration: January 21, 2027

[REDACTED] [REDACTED]
[REDACTED] [REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]

[REDACTED]
[REDACTED]

5.6 [1785620-10] Genetically Engineered Nanoscale Biosensors Immobilized in Diatom Biosilica

PI: Nicole Ford, PhD

[REDACTED] [REDACTED]

Submission Type: Other

Review Type: Administrative Review
Action: Approved
Effective Date: May 15, 2026
Project Status: Active
Project Expiration: July 23, 2026

[REDACTED] [REDACTED]
[REDACTED] [REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]

[REDACTED]
[REDACTED]

5.7 [731270-56] Angiogenesis

PI: Eugene Konorev, MD, PhD
Submission Type: Other

Review Type: Administrative Review
Action: Approved
Effective Date: May 15, 2026
Project Status: Active
Project Expiration: February 18, 2027

[REDACTED]
[REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]
[REDACTED]

[REDACTED]

5.8 [2053161-10] PXR expression and activation in human breast cancers

PI: Bradley Creamer, PhD
Submission Type: Other

Review Type: Administrative Review
Action: Approved
Effective Date: June 15, 2026
Project Status: Active
Project Expiration: March 25, 2027

[REDACTED]
[REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

5.9 [2407920-4] Stromal 12-Lipoxygenase as a Therapeutic Target in Pancreatic Cancer

PI: Ehab Sarsour, Msc., PhD
Submission Type: New Project

Review Type: Administrative Review
Action: Acknowledged
Effective Date: June 8, 2026
Project Status: Active
Project Expiration: May 20, 2027

[REDACTED]
[REDACTED]

Discussion and Remarks:

The PI resubmitted the IBC application and the rDNA with the IBC Committee requested modifications and information and the conditional approval was removed as of 06/08/2026.

5.10 **[1194016-54] scaRNAs regulate spliceosome fidelity, alternative splicing of mRNA and embryological development.**

PI: Douglas Bittel, Ph.D.

[REDACTED]

Submission Type: Other

Review Type: Administrative Review
Action: Approved
Effective Date: June 9, 2026
Project Status: Active
Project Expiration: February 18, 2027

[REDACTED]
[REDACTED]

Discussion and Remarks:

The addition of personnel was administratively reviewed and approved [REDACTED]

[REDACTED]

I [REDACTED]

6 **Old Business**

7 **New Business**

7.1 **[2185780-23] Cadaveric Anatomical Research Framework**

PI: Robert Hillard, MD
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: June 25, 2026
Project Status: Active

Project Expiration: June 24, 2027
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Recused = 1 (Farida Mehrhoff)

[REDACTED]
[REDACTED]

Discussion and Remarks:

[REDACTED]
[REDACTED] motioned to approve and [REDACTED] seconded. All voted in favor and motion was approved to renew the study.

The renewal was approved under bio-safety level BSL-1 because the cadavers are formalin embalmed.

7.2 [754478-69] Neurodegenerative Disorders and Aging

PI: Abdulbaki AGBAS, M.Sc.,Ph.D.
Submission Type: Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: June 25, 2026
Project Status: Active
Project Expiration: June 24, 2027
Vote: Total = 6; For = 6; Opposed = 0; Abstained = 0;
Recused = 1 (Abdulbaki Agbas)

[REDACTED]
[REDACTED]

Discussion and Remarks:

[REDACTED]
[REDACTED] made a motion to approve the renewal of the study and [REDACTED] seconded. All voted in favor and motion was approved.

The renewal was approved under bio-safety level BSL-2 and exempt under Section III-F-8 of the NIH Guidelines

8 Other Business

8.1 Discussion about the IBC oversight of carcinogen and chemotherapy drugs and any other chemicals.

The committee discussed the IBC oversight of carcinogen and chemotherapy drugs and any other chemicals and agreed to continue to be conducted by this committee. The group concurred a

separate committee was not needed for this institution and could continue to be overseen as it was presently. It was suggested that a question could be added to the form under the new IBC platform to remove the need to complete a portion of the form if only chemicals were being used. [REDACTED] will work on that item and present at a later time to the committee.

8.2 The Bio-safety Officer Report

The Bio-safety Officer had nothing to report.

9 Adjourn

The meeting adjourned on June 25, 2026 at 1:03 PM.